Published in Gene Therapy Weekly, February 3rd, 1997
"This exciting new technology will boost our efforts to overcome the technical difficulties related to the injectability of retroviral vectors, and further strengthen our lead in the development of true in vivo gene therapy," said Dr. Paul Herrling, Novartis Pharma Research. "Much of GTI's research focuses on targetable, injectable, regulatable vectors which are of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.